Clinical Trial Detail

NCT ID NCT01667419
Title BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

melanoma

Therapies

Vemurafenib

Age Groups: adult

No variant requirements are available.